235 related articles for article (PubMed ID: 32724460)
1. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
2. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Tong J; Tan S; Zou F; Yu J; Zhang L
Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells.
Tong J; Wang P; Tan S; Chen D; Nikolovska-Coleska Z; Zou F; Yu J; Zhang L
Cancer Res; 2017 May; 77(9):2512-2521. PubMed ID: 28202514
[TBL] [Abstract][Full Text] [Related]
4. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
5.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
7. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
[TBL] [Abstract][Full Text] [Related]
10. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
[TBL] [Abstract][Full Text] [Related]
14. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
[TBL] [Abstract][Full Text] [Related]
15. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Merino D; Whittle JR; Vaillant F; Serrano A; Gong JN; Giner G; Maragno AL; Chanrion M; Schneider E; Pal B; Li X; Dewson G; Gräsel J; Liu K; Lalaoui N; Segal D; Herold MJ; Huang DCS; Smyth GK; Geneste O; Lessene G; Visvader JE; Lindeman GJ
Sci Transl Med; 2017 Aug; 9(401):. PubMed ID: 28768804
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
[TBL] [Abstract][Full Text] [Related]
17. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
[TBL] [Abstract][Full Text] [Related]
18. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]